Critical Medicines Act: Council and Parliament Reach Provisional Deal
Decision brief
Answer first · skim in under a minute
The Council and Parliament have reached a provisional deal on the Critical Medicines Act, marking a significant development in pharmaceutical regulation. This article analyzes the market implications for BD teams, investors, and analysts.
Council and Parliament reached a provisional deal on the Critical Medicines Act on 12 May 2026, aiming to harden EU supply of essential drugs such as antibiotics, insulin, and vaccines. EMA welcomed the political agreement while stressing that formal adoption still lies ahead.
Contents9 sections
Key Takeaways
- Provisional CMA agreement dated 12 May 2026 between Parliament and Council negotiators.
- Focus: EU manufacturing strategic projects, procurement favoring supply resilience, and collaborative buying when five or more Member States request it.
- EMA ties implementation to MSSG vulnerability assessments and the Union list of critical medicines (200+ active substances).
- Rules are not yet in force pending formal institutional approval.
What did co-legislators agree?
EMA's 12 May 2026 statement welcoming the Critical Medicines Act agreement describes a milestone for resilience, security, and sustainability of critical-medicine supply.
The Commission's Critical Medicines Act public-health page frames the March 2025 proposal as a European Health Union tool that complements pharmaceutical-legislation reform. Over 50% of reported shortages link to manufacturing issues, including active-substance gaps, according to Parliament's deal summary cited by EMA's related links.
Which industrial and procurement tools matter for BD?
Negotiators agreed criteria for EU-based industrial “strategic projects” that create, modernize, or expand manufacturing capacity for critical medicines or APIs. Firms taking national or EU support must prioritize EU-market supply.
- Procurement rules should diversify supply sources for critical medicines and APIs.
- Where dependency on third countries is high, authorities may reward EU manufacturing share.
- The Commission must launch collaborative procurement when five or more Member States request it.
Orphan medicines can benefit from strategic-project and collaborative-procurement opportunities under the deal narrative EMA and Commission materials reference.
How does EMA say it will operationalize the Act?
EMA says the Act foreshadows a role for the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) in supply-chain vulnerability assessments. MSSG is already evaluating vulnerabilities for a first set of medicines on the Union list of critical medicines.
EMA is also expanding the European Shortages Monitoring Platform (ESMP) and points to the Quality Innovation Expert Group (QIG) as a recognized partner for innovative manufacturing technologies.
What should manufacturers and investors watch next?
Track formal Parliament and Council votes, implementing acts on strategic-project designation, and state-aid guidance. Companies with EU API or finished-dose capacity may gain procurement preference; importers reliant on single third-country sources face diversification pressure.
The Commission proposal text remains available via COM(2025) 102 final on health.ec.europa.eu for baseline scope against the Union list of critical medicinal products.
What remains unproven after the provisional deal?
A political agreement is not final law. Funding envelopes, permitting timelines, and how aggressively “Buy European” scoring will work in practice are still unsettled. Shortage reduction will depend on Member State uptake of collaborative procurement and industry willingness to site capacity in the EU.
Related NovaPharma coverage
- PRAC Meeting Highlights: May 2026 Updates
- May 2026 Regulatory Actions: Key Pharma Updates
- Italy's Clinical Research Landscape
Frequently Asked Questions
When did Council and Parliament reach a Critical Medicines Act deal?
On 12 May 2026, European Parliament and Council negotiators reached a provisional political agreement on the Critical Medicines Act. EMA welcomed the agreement the same day.
What does the Critical Medicines Act aim to fix?
The Act aims to improve availability, production, and supply of critical medicines in the EU, reduce third-country dependency, support EU manufacturing strategic projects, and enable collaborative procurement, including for some medicines of common interest and orphans.
Is the Critical Medicines Act already in force?
No. The provisional agreement still requires formal approval by Parliament and Council before the regulation can enter into force.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
